Researchers at the University of Oregon synthesized organic molecules that break down and release hydrogen sulfide under certain biological conditions such as oxidative stress, and may protect cells.
Parkinson’s disease patients who are treated with deep brain stimulation may require fewer surgeries to replace the batteries in their stimulation devices thanks to a more energy-efficient stimulation approach developed by Duke University scientists. The optimized stimulation could be also used to develop patterns that are tailored to treat specific…
The U.S. Food and Drug Administration (FDA) has agreed to review a request by Adamas Pharmaceuticals to approve ADS-5102 (amantadine hydrochloride) extended-release capsules to treat levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). The company submitted the request as New Drug Application (NDA) to the FDA in October. A…
A Phase 3 clinical trial (NCT01227655) in Parkinson’s disease patients on levodopa treatment showed that Bial’s Ongentys (opicapone) reduced the fluctuations in drug effect that are a hallmark of levodopa treatment, according to a recent study that evaluated trial data. Patients who received Ongentys had less off-time, meaning…
Richard Myers, a Boston University School of Medicine (BUSM) professor of neurology, has just received a $100,000 grant from the Ellison Foundation to investigate new targets for Parkinson’s disease (PD). Myers’ focus is on genetic research methods into diseases with adult onset, like PD, Huntington’s, or obesity. His research team has been examining the…
Researchers have discovered that a protein called Nrf2 is capable of maintaining healthy levels of certain proteins linked to Parkinson’s disease, so as to protect neurons from cell death. The research could lead to new therapeutic targets for Parkinson’s and other neurodegenerative diseases. The study, “Nrf2 mitigates LRRK2- and α-synuclein–induced…
Researchers have discovered that welders develop symptoms of parkinsonism — a general term referring to disorders that cause movement problems that resemble those of Parkinson’s disease — because of prolonged exposure to manganese, a chemical element from welding fumes. The finding was reported in the study “Dose-dependent progression of parkinsonism…
PRX002, a drug candidate under development for the potential treatment of Parkinson’s disease is safe and well tolerated, according to the results of a Phase 1 clinical trial (NCT02095171) conducted on healthy volunteers and published in the scientific journal Movement Disorders.
An international post-mortem brain study of Parkinson’s disease shows altered levels of the LRRK2 protein are associated with different stages of the disease. The study, “LRRK2 levels and phosphorylation in Parkinson’s disease brain and cases with restricted Lewy bodies,” was published in the journal Movement Disorders. Previous studies…
President Obama recently signed into law the $6.3 billion 21st Century Cures Act, giving the U.S. Food and Drug Administration (FDA) more leeway to work with pharmaceutical companies and evaluate new treatments, including stem cell therapies. The “Moonshot” bill, named in memory of Vice President Joe Biden’s son Beau, who lost his…
Get regular updates to your inbox.
